These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30517989)

  • 1. Immune checkpoint inhibitor-induced lymphocytic fasciitis.
    Rischin A; Brady B; McLean C; Ostor AJK
    Intern Med J; 2018 Dec; 48(12):1550-1552. PubMed ID: 30517989
    [No Abstract]   [Full Text] [Related]  

  • 2. Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
    Yamaguchi S; Morimoto R; Okumura T; Yamashita Y; Haga T; Kuwayama T; Yokoi T; Hiraiwa H; Kondo T; Sugiura Y; Watanabe N; Kano N; Kohno K; Fukaya K; Sawamura A; Yokota K; Ishii H; Nakaguro M; Akiyama M; Murohara T
    Can J Cardiol; 2018 Jun; 34(6):812.e1-812.e3. PubMed ID: 29801747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab.
    Martinot M; Ahle G; Petrosyan I; Martinez C; Gorun DM; Mohseni-Zadeh M; Fafi-Kremer S; Tebacher-Alt M
    Emerg Infect Dis; 2018 Aug; 24(8):1594-1596. PubMed ID: 30016251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic effect of nivolumab against melanoma and immune-related liver toxicity: A detailed histopathological and immunohistochemical analysis of nivolumab-induced liver toxicity.
    Namiki T; Nojima K; Chikazawa S; Iwamoto Y; Otsuki Y; Albusani H; Miura K; Kiyokawa Y; Asakage T; Yokozeki H
    J Dermatol; 2019 May; 46(5):e182-e183. PubMed ID: 30474878
    [No Abstract]   [Full Text] [Related]  

  • 5. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
    Abdullah HMA; Elnair R; Khan UI; Omar M; Morey-Vargas OL
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.
    Widick P; Gill RR; Mantia C; Costa DB; Rangachari D
    Clin Lung Cancer; 2020 Jan; 21(1):e6-e9. PubMed ID: 31640925
    [No Abstract]   [Full Text] [Related]  

  • 7. Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.
    Parakh S; Cebon J; Klein O
    Oncologist; 2018 Jul; 23(7):849-851. PubMed ID: 29666298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
    Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
    J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
    Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
    Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.
    Tadokoro T; Keshino E; Makiyama A; Sasaguri T; Ohshima K; Katano H; Mohri M
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27650418
    [No Abstract]   [Full Text] [Related]  

  • 11. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
    Hida T
    Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor.
    Quresh Q; Quinet R
    J Clin Rheumatol; 2017 Jun; 23(4):235. PubMed ID: 28538282
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperprogression after nivolumab for melanoma: A case report.
    Yilmaz M; Akovali B
    J Oncol Pharm Pract; 2020 Jan; 26(1):244-251. PubMed ID: 31068087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.
    Dehghani L; Mikail N; Kramkimel N; Soyer P; Lebtahi R; Mallone R; Larger E
    Eur J Cancer; 2018 Nov; 104():243-246. PubMed ID: 30454710
    [No Abstract]   [Full Text] [Related]  

  • 15. Nivolumab for the treatment of urothelial cancers.
    Teo MY; Rosenberg JE
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):215-221. PubMed ID: 29363363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.
    Ziemer M; Koukoulioti E; Beyer S; Simon JC; Berg T
    J Hepatol; 2017 Mar; 66(3):657-659. PubMed ID: 27908801
    [No Abstract]   [Full Text] [Related]  

  • 17. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
    So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
    J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
    [No Abstract]   [Full Text] [Related]  

  • 18. A Rare Side Effect of Checkpoint Inhibitor Therapy-Nivolumab-Induced Axial Polyarthritis of the Facet and Costovertebral Joints.
    Feist J; Murray A; Skapenko A; Schulze-Koops H
    Arthritis Rheumatol; 2019 Nov; 71(11):1823. PubMed ID: 31297971
    [No Abstract]   [Full Text] [Related]  

  • 19. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.
    Teramoto Y; Nakamura Y; Asami Y; Imamura T; Takahira S; Nemoto M; Sakai G; Shimada A; Noda M; Yamamoto A
    J Dermatol; 2017 May; 44(5):605-606. PubMed ID: 27334247
    [No Abstract]   [Full Text] [Related]  

  • 20. Angioedema late in the course of adjuvant nivolumab therapy for melanoma.
    Ratra A; Dasanu CA
    J Oncol Pharm Pract; 2020 Jun; 26(4):1019-1021. PubMed ID: 31635547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.